Lonza
Lonza Group AG, commonly referred to as Lonza, is a leading global provider of integrated solutions for the pharmaceutical, biotechnology, and specialty ingredients sectors. Headquartered in Switzerland (CH), Lonza operates extensively across Europe, North America, and Asia, delivering innovative products and services that cater to diverse industry needs. Founded in 1897, Lonza has achieved significant milestones, including advancements in cell and gene therapy manufacturing. The company is renowned for its high-quality contract development and manufacturing services (CDMO), as well as its extensive portfolio of active pharmaceutical ingredients (APIs) and custom manufacturing solutions. Lonza's commitment to sustainability and cutting-edge technology positions it as a market leader, consistently recognised for its contributions to the life sciences and healthcare industries.
DitchCarbon Score
How does Lonza's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Furniture Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Lonza's score of 50 is higher than 95% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Lonza's reported carbon emissions
In 2023, Lonza Group Ltd, headquartered in Switzerland (CH), reported total greenhouse gas emissions of approximately 3,190,000 kg CO2e for Scope 1, 202,000 kg CO2e for Scope 2 (market-based), and 1,876,000,000 kg CO2e for Scope 3 emissions. The company has set ambitious climate commitments, aiming to achieve carbon neutrality by 2050. Lonza has established a near-term target to reduce absolute Scope 1 and 2 emissions by 42% by 2030, using 2021 as the base year. Additionally, they aim to ensure that 79% of their suppliers, based on emissions from purchased goods and services, capital goods, and upstream transportation, will have science-based targets by 2028. The company also targets a 50% reduction in greenhouse gas intensity (Scope 1 and 2) per CHF 1 million in sales by 2030, with 2018 as the base year. These initiatives reflect Lonza's commitment to sustainability and reducing its overall carbon footprint in the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 574,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 348,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 33,000,000 | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Lonza is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
